SCHEMBL6329466

SCHEMBL6329466

CCC(=O)c1ccc2sccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 4/20 0.65
WNT3A P56704 4/20 0.65
ATM Q13315 1/20 0.46
NAMPT P43490 1/20 0.45
CYP2A6 P11509 2/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6327569 0.87 CTNNB1 (0.70) CTNNB1WNT3ANAMPTCYP2A6SLC6A2
SCHEMBL6335648 0.86 CTNNB1 (0.49) CTNNB1WNT3AATMSIGMAR1MRGPRX4
SCHEMBL25570140 0.83 CTNNB1 (0.57) CTNNB1WNT3ANAMPTCYP2A6SLC6A2
SCHEMBL3499359 0.83 CTNNB1 (0.65) CTNNB1WNT3ANAMPTCYP2A6MRGPRX4
SCHEMBL25570121 0.82 CTNNB1 (0.60) CTNNB1WNT3ANAMPTCYP2A6SLC6A2
SCHEMBL6329867 0.82 CTNNB1 (0.60) CTNNB1WNT3ANAMPTCYP2A6MRGPRX4
SCHEMBL15980113 0.81 CTNNB1 (0.76) CTNNB1WNT3ANAMPTCA12CA2
SCHEMBL826934 0.80 CTNNB1 (0.57) CTNNB1WNT3ANAMPTCYP2A6CA2
SCHEMBL30446776 0.80 CTNNB1 (0.57) CTNNB1WNT3ANAMPTCYP2A6CA2
SCHEMBL2085275 0.79 CA12 (0.53) CTNNB1WNT3ACA12CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459912-B2 Advantageous benzothiophene compositions for mental disorders or enhancement TACTOGEN INC (US) 2025-11-04 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
EP-4175638-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT Tactogen Inc. (US) 2023-05-10 EP disclosed
CN-116096715-A Beneficial benzothiophene compositions for mental disorders or enhancement 泰科根公司 2023-05-09 CN disclosed
US-20130196978-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2013-08-01 US disclosed
US-20130172302-A1 QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2013-07-04 US disclosed
US-6900216-B2 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents KNOLL GMBH (DE) 2005-05-31 US disclosed
US-20030166628-A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents KNOLL GMBH (DE) 2003-09-04 US disclosed
EP-1268489-A1 DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS Knoll GmbH (DE) 2003-01-02 EP disclosed
WO-2001068653-A1 DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS KNOLL GMBH (DE) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT SLC6A3, CREBBP, SLC1A2 CTNNB1 2458/4885WNT3A 1865/4885ATM 2416/4885
US-20130196978-A1 ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF CHRM3, CHRM1, CHRNG CTNNB1 3654/4885WNT3A 3469/4885ATM 771/4885
US-20130172302-A1 QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF CHRM1, CHRM2, CHRM3 CTNNB1 4329/4885WNT3A 3495/4885ATM 4204/4885
US-20030166628-A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents GPR119, HTR3B, HTR2B CTNNB1 668/4885WNT3A 1820/4885ATM 1759/4885
US-12459912-B2 Advantageous benzothiophene compositions for mental disorders or enhancement SLC6A3, CREBBP, SLC1A2 CTNNB1 2458/4885WNT3A 1865/4885ATM 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.